All News
Filter News
Found 622 articles
-
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
2/8/2018
Regeneron today announced financial results for the fourth quarter and full year 2017 and provided a business update.
-
Sanofi Delivers 2017 Business EPS in Line With Guidance
2/7/2018
Fourth-quarter and 2017 accounts reflect the acquisition of the former Boehringer Ingelheim CHC business and the disposal of the Animal Health business.
-
Sanofi Delivers 2017 Business EPS(1) in Line With Guidance
2/7/2018
Fourth-quarter and 2017 accounts reflect the acquisition of the former Boehringer Ingelheim Consumer Healthcare (CHC) business.
-
Sanofi to Eliminate 400 U.S. Jobs
1/22/2018
Sanofi has announced major restructuring, which will involve layoffs. -
Regeneron Announces Approval of DUPIXENT (dupilumab) in Japan for the Treatment of Atopic Dermatitis
1/22/2018
Regeneron today announced that the MHLW in Japan has granted marketing and manufacturing authorization for DUPIXENT for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies.
-
Regeneron Keeps Science at the Center
1/17/2018
Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them. -
This build out of the executive team follows the closing of a $30 million Series B financing announced last year.
-
The two companies struck the deal in 2015.
-
The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.
-
Sanofi Presents R&D Strategy and Innovative Pipeline
12/13/2017
The company will highlight the progress it has made against "Sustaining Innovation", a key pillar of its 2020 strategic roadmap, and advancing a differentiated portfolio addressing unmet needs.
-
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day
12/13/2017
In a separate release today the companies also shared positive topline results for PD-1 antibody cemiplimab in advanced CSCC.
-
When complete, the expansion is expected to double the size of Regeneron's footprint in Greenburgh.
-
Regeneron Reports Third Quarter 2017 Financial and Operating Results
11/8/2017
In the third quarter of 2017, net sales of EYLEA in the United States increased 12% to $953M from $854M in the third quarter of 2016.
-
Despite Brandicourt's positive spin, investors were displeased as the company's financial report fell shy of analysts' expectations.
-
Sanofi: Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function i...
10/31/2017
Dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70% on average. -
New positions have been announced at Regeneron as the company’s Irish bioprocessing campus receives an additional $100m in funding.
-
Regeneron And Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
10/16/2017
Regeneron and Sanofi today announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis.
-
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
10/16/2017
Aimmune Therapeutics, Inc., today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to study AR101 treatment with adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical trial.
-
2 Biotechs That Turned $7,000 Into $130,200 for Investors
10/2/2017
-
Regeneron And Sanofi Announce Approval Of DUPIXENT (Dupilumab) To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis In The European Union
9/28/2017